TP53 and endometrioid adenocarcinoma: Moreover, the targeted NGS analysis identified the TP53 gene missense mutation c.614A > G p.(Tyr205Cys) in NEC (VAF 81.7%), endometrioid carcinoma (VAF 59.3%), and ovarian endometriosis (VAF 18.1%), not detected in EAH of the endometrium (Fig. 3).